Checkpoint inhibitor usage in U.S. patients by tumor type 2017
This statistic shows percentage of U.S. patients treated with PD-1 and PD-L1 checkpoint inhibitors in 2018, by tumor type. According to the data, 52.4 percent of patients treated with PD-1 and PD-L1 checkpoint inhibitors were for lung tumors.